Exact Sciences (NASDAQ: EXAS) reported Q1 EPS of ($0.71), $0.10 worse than the analyst estimate of ($0.61). Revenue for the quarter came in at $347.8 million versus the consensus estimate of $350.39 million.

For earnings history and earnings-related data on Exact Sciences (EXAS) click here.